Dr
Clara
Orofino Peña

Patent Attorney

Glasgow Office

Telephone. +44(0) 141 229 5800
Email. [email protected]

Experience

Clara has extensive experience drafting and prosecuting patent applications in the fields of pharmaceuticals, oil and gas, process Chemistry, materials Chemistry, textiles, batteries and fuel cells, surfactants, medical devices, and other mechanical devices.

She manages global IP portfolios in a variety of technologies for universities and SMEs, and her main body of work is European and UK patent drafting and prosecution for multinationals and foreign associates. Clara also has experience in patentability and freedom to operate opinions, European patent oppositions and appeals.

Clara speaks multiple languages and enjoys providing focused technical and commercial advice to her clients.

Specialisms

  • Electrochemistry
  • Energy
  • Material science
  • Petrochemicals
  • Pharmaceutical technologies
  • Physical chemistry

Industries

  • Medical devices icon Medical devices
  • Operations icon Operations
  • Pharmaceuticals icon Pharmaceuticals

Services

  • Designs & design rights
  • Patent oppositions & appeals
  • Patents
  • Portfolio management
  • Searching & competitor monitoring
  • Strategy

Qualifications

Patent Attorney

European


BSC

Pure and Applied Chemistry - University of Strathclyde

OTHER

Licenciatura en Quimica (Equivalent to MSci in Pure and Applied Chemistry) - University of the Basque Country

PHD

PhD in Materials Chemistry - University of Strathclyde

POSTGRADUATE DIPLOMA OR CERTIFICATE

IPRegs Intellectual Property Litigation Certificate (UK)

CSR

Clara mentors trainees on daily drafting and prosecution matters and has delivered tutorials for the EQEs.

Related News

EPO Enlarged Board of Appeal decision G4/19 - a European patent application can be refused by reason of the prohibition on double patenting

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can …

Read article

Managing Intellectual Property IP Stars & Firm Rankings 2021

Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …

Read article

Medical technology most patented subject matter at EPO in 2020

Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …

Read article

The EPO ‘How To’ guide for antibody applications in Europe

The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …

Read article

Personalised drug patenting in Europe

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …

Read article

The Internet of Medical Things

Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …

Read article

Covid-19 vaccine patent waivers

To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …

Read article

G1/21 hearing at the EPO

Follow this page for the updates from G1/21 hearing at the EPO on 28th May 2021. HGF Partners Dr Chris Moore and Douglas Drysdale will be reporting all the key …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.